In critically ill patients with COVID-19, IL-6 receptor antagonists reduced mortality vs. control at 180 d.

Authors
Category Primary study
JournalAnnals of internal medicine
Year 2023
Writing Committee for the REMAP-CAP Investigators; Higgins AM, Berry LR, Lorenzi E, et al. Long-term (180-day) outcomes in critically ill patients with COVID-19 in the REMAP-CAP randomized clinical trial. JAMA. 2023;329:39-51. 36525245.
Epistemonikos ID: 7f1f1504c925cd5031a87693b67e8e737837b641
First added on: Apr 03, 2023